8EV Stock Chart & Stats
€0.02
<€0.01(80.00%)
At close: 4:00 PM EDT
€0.02
<€0.01(80.00%)
Day’s Range― - ―
52-Week Range€0.00 - €0.02
Previous CloseN/A
Volume3.00K
Average Volume (3M)N/A
Market Cap
€5.80M
Enterprise Value€2.66M
Total Cash (Recent Filing)€1.54M
Total Debt (Recent Filing)€11.00K
Price to Earnings (P/E)―
Beta-25.38
Next Earnings
Dec 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,732,297,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Drug-discovery PlatformOwnership of the Sulforadex platform gives Evgen a defined technology base from which to develop multiple therapeutics. Its application across oncology and inflammatory or disease areas may support a broader development strategy and create future partnering opportunities.
Pipeline Across Multiple Therapeutic AreasA pipeline spanning breast cancer and additional programmes gives the company more than one potential route to clinical value creation. Progress in any candidate could strengthen the platform’s credibility, support licensing discussions, and improve long-term commercial optionality.
Minimal Reported DebtMinimal reported debt limits fixed financial obligations and reduces balance-sheet pressure compared with a highly leveraged development company. This provides some flexibility in allocating available funds to research and clinical work, although it does not remove the need for future financing.
Bears Say
Persistent Operating LossesPersistent operating and net losses show that the company has not yet converted its development activities into sustainable profitability. The larger reported loss in 2026 increases uncertainty around the path to breakeven and may constrain internal funding for pipeline advancement.
Ongoing Cash BurnNegative operating and free cash flow indicate that the business is not self-funding its research and development programme. Continued cash consumption increases reliance on external capital, making financing execution important and creating potential dilution risk if losses persist.
Shrinking Balance-sheet CushionThe substantial decline in equity and the downward trend in assets indicate that prior losses have consumed part of the company’s financial cushion. A thinner balance sheet reduces resilience, limits flexibility during development setbacks, and may increase the urgency of future fundraising.
Evgen Pharma News
8EV FAQ
What was Evgen Pharma PLC’s price range in the past 12 months?
Evgen Pharma PLC lowest stock price was €0.00 and its highest was €0.02 in the past 12 months.
What is Evgen Pharma PLC’s market cap?
Evgen Pharma PLC’s market cap is €5.80M.
When is Evgen Pharma PLC’s upcoming earnings report date?
Evgen Pharma PLC’s upcoming earnings report date is Dec 09, 2026 which is in 63 days.
How were Evgen Pharma PLC’s earnings last quarter?
Evgen Pharma PLC released its earnings results on Jun 10, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Evgen Pharma PLC overvalued?
According to Wall Street analysts Evgen Pharma PLC’s price is currently Overvalued.
Does Evgen Pharma PLC pay dividends?
Evgen Pharma PLC does not currently pay dividends.
What is Evgen Pharma PLC’s EPS estimate?
Evgen Pharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evgen Pharma PLC have?
Evgen Pharma PLC has 2,732,297,000 shares outstanding.
What happened to Evgen Pharma PLC’s price movement after its last earnings report?
Evgen Pharma PLC reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went down -12.903%.
Which hedge fund is a major shareholder of Evgen Pharma PLC?
Currently, no hedge funds are holding shares in DE:8EV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evgen Pharma PLC
Theracryf Plc operates as a clinical-stage biotechnology firm, dedicated to advancing treatments for oncological diseases and various brain disorders affecting behavior. Its primary therapeutic asset, SFX-01, is currently progressing through Phase II clinical trials for metastatic breast cancer. Additionally, SFX-01 is in Phase I trials for neurodevelopmental conditions and glioblastoma, and is undergoing preclinical investigation for rhabdomyosarcoma. The company's pipeline also includes an orexin 1 antagonist, which is in the late preclinical stage for addressing addiction and anxiety, alongside an atypical dopamine transporter inhibitor (DAT) at a similar development stage, targeting fatigue and narcolepsy. Incorporated in 2014 and headquartered in Nether Alderley, United Kingdom, the company rebranded from Evgen Pharma plc to Theracryf Plc in April 2024.
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
ValiRx plc
―